Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: A cohort study.

Birabaharan, Morgan; Kaelber, David C; Karris, Maile Y

Birabaharan, Morgan; Kaelber, David C; Karris, Maile Y.

Afiliação

Birabaharan M; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California. Electronic address: mbirabaharan39@gmail.com.
Kaelber DC; Departments of Internal Medicine, Pediatrics, and Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio; Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio.
Karris MY; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California.

J Am Acad Dermatol ; 87(3): 649-651, 2022 09.

Article em En | MEDLINE | ID: mdl-34826538

Assuntos

Vacinas contra COVID-19; COVID-19; Herpes Zoster; COVID-19/prevenção & controle; Vacinas contra COVID-19/efeitos adversos; Estudos de Coortes; Herpes Zoster/epidemiologia; Herpes Zoster/prevenção & controle; Vacina contra Herpes Zoster/efeitos adversos; Herpesvirus Humano 3; Humanos; RNA Mensageiro; Vacinação/efeitos adversos; Vacinas de mRNA/efeitos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 / Herpes Zoster Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google